Filing Details
- Accession Number:
- 0001181431-13-039894
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-07-15 10:53:37
- Reporting Period:
- 2013-07-12
- Filing Date:
- 2013-07-15
- Accepted Time:
- 2013-07-15 10:53:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1396814 | Pacira Pharmaceuticals Inc. | PCRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1545282 | Taunia Markvicka | C/O Pacira Pharmaceuticals, Inc. 5 Sylvan Way, Suite 100 Parsippany NJ 07054 | Vice President, Commercial | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-07-12 | 29,754 | $1.61 | 29,754 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-07-12 | 29,754 | $32.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2013-07-12 | 29,754 | $0.00 | 29,754 | $1.61 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2020-09-01 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The stock option vested as follows: 50% of the shares vested upon the date of grant; the remaining shares vested in monthly installments over the succeeding 24 months.